An evaluation of the FDA Responder Endpoint for IBS‐C clinical trials: analysis of data from linaclotide Phase 3 clinical trialsJ MacDougall, Anthony J Lembo, Bernard J. Lavins et al.|Neurogastroenterology & Motility|2013Cited by 30